Gary Tin Email and Phone Number

Supervisor: Dr. Georg Winter- Participated in industry collaboration with Pfizer’s team led by Monica Schenone. - Performed large-scale fragment screening with an alkyne-diazirine library (~400 fragments), followed by quantitative proteomics and downstream target deconvolution - Spearheaded medicinal chemistry efforts to together with Pfizer and CRO-WuXi to design and direct synthesis of small molecule targets of selected fragments utilizing structure-based design (QSAR)… Show more Supervisor: Dr. Georg Winter- Participated in industry collaboration with Pfizer’s team led by Monica Schenone. - Performed large-scale fragment screening with an alkyne-diazirine library (~400 fragments), followed by quantitative proteomics and downstream target deconvolution - Spearheaded medicinal chemistry efforts to together with Pfizer and CRO-WuXi to design and direct synthesis of small molecule targets of selected fragments utilizing structure-based design (QSAR) including optimizations of drug-likeness, minimizing cLogP, enhancing solubility, and bioisoteric replacements for enhanced ligand binding- Further validation of selected fragment-protein pairs by competitive proteomics/WBs, orthogonal functional assays, and computational modelling to guide compound design- Designed and synthesized multiple PROTACs, proximity-inducing and covalent molecules against various targets towards degradation and complex cellular responses - Implemented modern medicinal chemistry design principles onto degraders; changing flexible chains to rigid linkers, phenyl group replacement to sp3-rich spirocycles to facilitate solubility, enhance binding affinity, and improve in-vivo stability- Target ID and mechanism validation of selected degraders via functional genomics including CRISPR-based screens, cellular-KOs and inhibitor-based rescue experiments related to targeted protein degradation Show less

- Bioorganic medicinal chemistry exploring covalent therapeutics towards transcription factors (STAT3 + STAT5) and cancer targets (tubulin)- Developed novel covalent chemistry platform for selective tuning of pentafluorobenzenesulfonamide warheads for in-vivo applications- Successfully exemplified that a failed pentafluorobenzenesulfonamide-containing clinical candidate (Batabulin, T138067), can be rescued by tempering its reactivity and thus, significantly improving its t1/2 up to… Show more - Bioorganic medicinal chemistry exploring covalent therapeutics towards transcription factors (STAT3 + STAT5) and cancer targets (tubulin)- Developed novel covalent chemistry platform for selective tuning of pentafluorobenzenesulfonamide warheads for in-vivo applications- Successfully exemplified that a failed pentafluorobenzenesulfonamide-containing clinical candidate (Batabulin, T138067), can be rescued by tempering its reactivity and thus, significantly improving its t1/2 up to 7-fold- Inventor of 2 patents summarizing my PhD work, and subsequently helped to pitch the platform to investors resulting in academic spin-offs, Dalriada and Dunad Therapeutics Show less

- Participated in CRO-based projects as member of custom organic synthesis team - Worked under SOP and GLP guidelines for synthesizing small molecules- Optimized purification protocols and characterization of compounds using industry-standard NMR, HPLC and LC-MS-based analytical methodologies

- Designed small molecule library towards treatment of Alzheimer’s disease- Performed synthesis, analysis and biological assay testing of a novel class of phenothiazine-based with multi-target functionalities including cholinesterase inhibition, amyloid aggregation inhibition and antioxidant properites- Utilized modern computational modelling and QSAR to guide molecule design

- Led a collaborative project between academia and industry to re-evaluate novel mechanisms of amyloid-beta aggregation using existing SSRI therapies.- Utilized computational pipeline of Cyclica’s proprietary Ligand Express™ platform- Developed and validated Cyclica’s platform towards drug discovery